The American Journal of Managed Care

FDA Approves FoundationOne Liquid CDx as a Diagnostic Tool for BRCA-Mutated mCRPC

FoundationOne Liquid CDx can be used to identify niraparib and abiraterone acetate eligibility in patients with metastatic castration-resistant prostate cancer (mCRPC). According to the American ...

Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous ...

Foundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE: BMY) to develop FoundationOne®CDx as a ...
The American Journal of Managed Care

FDA Approves FoundationOne CDx as Companion Diagnostic for Niraparib/Abiraterone in mCRPC

The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) ...
Nasdaq

Foundation Medicine Receives FDA Approval for FoundationOne®CDx as the Companion Diagnostic for LYNPARZA® to Identify Patients with HRR-Mutated Metastatic Castration ...

LYNPARZA was approved based on positive results from the PROfound study for which Foundation Medicine served as the Next-Generation Sequencing (NGS) partner Prostate cancer is the second most common ...
Business Wire

U.S. FDA Approves FoundationOne®CDx as a Companion Diagnostic for EGFR Therapeutics Targeting Exon 19 Deletions or Exon 21 Substitutions in Non-Small Cell Lung Cancer

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc. a pioneer in molecular profiling for cancer, today announced it has received approval from the U.S. Food and Drug Administration (FDA) for ...
Healio

FDA approves FoundationOne CDx to identify patients with MSI-high tumors for pembrolizumab

Please provide your email address to receive an email when new articles are posted on . The FDA approved FoundationOne CDx as a companion diagnostic to identify patients with microsatellite ...
Business Wire

Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics

BOSTON & EL MONTE, Calif.--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced plans to launch two new germline tests, ...
Healio

FDA approves FoundationOne CDx test as companion diagnostic for Vitrakvi

Please provide your email address to receive an email when new articles are posted on . The FDA approved the FoundationOne CDx test to help identify certain neurotrophic receptor tyrosine kinase gene ...
Cure Today

FDA Approves Companion Diagnostic Device FoundationOne Liquid CDx for Patients with Prostate Cancer

The FDA approved this liquid biopsy to check blood for prostate-tumor DNA that indicates the presence of genetic mutations or rearrangements. The test was also recently approved for use in patients ...
Morningstar

Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker ...

Foundation Medicine Announces Expanded Participation in National Cancer Institute’s ComboMATCH Platform Trials Through Inclusion of Its High-Quality Blood-Based Biomarker Test, FoundationOne®Liquid ...
BioWorld

Items Tagged with 'Foundationone CDx'

Pillar Biosciences LLC hopes to build a stronger foundation for its multi-cancer in vitro diagnostic, Oncoreveal Dx. The company filed a supplemental application for U.S. FDA premarket approval of ...